Back to Studies

P1097 / Raltegravir PK Study

Raltegravir Pharmacokinetics and Safety in Neonates

Study Status


DAIDS Number


IND Number


Clinical Trials Link


P1097 is a Phase 0, multi-center washout pharmacokinetic trial of raltegravir in infants born to HIV-infected pregnant women. The study is designed to determine the washout pharmacokinetics and safety of in utero/intrapartum exposure following the infants for up to 20 weeks after birth.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...